Anticoagulation therapy in haemophilia

Hamostaseologie

Volumn 33, Issue 4, 2013, Pages 299-304

  Schutgens, R E G ^a   Tuinenburg, A ^a   Fischer, K ^a   Mauser Bunschoten, E P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anticoagulation; Aspirin; Atrial fibrillation; Cardiovascular disease; Coumarin; Haemophilia

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; COUMARIN DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; ANGINA PECTORIS; ANTICOAGULANT THERAPY; AORTA VALVE REPLACEMENT; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE REPORT; CHADS2 SCORE; CORONARY ARTERY ATHEROSCLEROSIS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMOPHILIA; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; OBESITY; PHENOTYPE; REVIEW; RISK ASSESSMENT; SCREENING; SMOKING; STABLE ANGINA PECTORIS; THROMBOSIS; UNITED STATES;

ANTICOAGULATION; ASPIRIN; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; COUMARIN; HAEMOPHILIA;

ANTICOAGULANTS; CAUSALITY; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; HEMOPHILIA A; HEMORRHAGE; HUMANS; RISK ASSESSMENT; THROMBOSIS;

EID: 84888407516     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-12-08-0015     Document Type: Review

References (46)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
2. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
4. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007; 14: 55-61.
5. Coughlin SR. Thrombin signalling and proteaseactivated receptors. Nature 2000; 407: 258-264.
6. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010; 30: 2357-2361.
7. Breitenstein A, Tanner FC, Luscher TF. Tissue factor and cardiovascular disease: quo vadis? Circ J 2010; 74: 3-12.
8. Tushuizen ME, Diamant M, Sturk A, Nieuwland R. Cell-derived microparticles in the pathogenesis of cardiovascular disease: friend or foe? Arterioscler Thromb Vasc Biol 2011; 31: 4-9.
9. Di Cera E. Thrombin as procoagulant and anticoagulant. J Thromb Haemost 2007; 5 (Suppl 1): 196-202.
10. Levi M, Schultz M, Van Der PT. Disseminated intravascular coagulation in infectious disease. Semin Thromb Hemost 2010; 36: 367-377.
11. Darby SC, Kan SW, Spooner RJ et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-825.
12. Koumbarelis E, Rosendaal FR, Gialeraki A et al. Epidemiology of haemophilia in Greece: an overview. Thromb Haemost 1994; 72: 808-813.
13. Plug I, Van Der Bom JG, Peters M et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006; 4: 510-516.
14. Rosendaal FR, Varekamp I, Smit C et al. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989; 71: 71-76.
15. Tagliaferri A, Rivolta GF, Iorio A et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-446.
16. Triemstra M, Rosendaal FR, Smit C et al. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995; 123: 823-827.
17. Tuinenburg A, Rutten A, Kavousi M et al. Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 799-804.
18. Biere-Rafi S, Tuinenburg A, Haak BW et al. Factor VIII deficiency does not protect against atherosclerosis. J Thromb Haemost 2012; 10: 30-37.
19. Coppola A, Tagliaferri A, Franchini M. The management of cardiovascular diseases in patients with hemophilia. Semin Thromb Hemost 2010; 36: 91-102.
20. Dolan G. The challenge of an ageing haemophilic population. Haemophilia 2010; 16 (Suppl 5): 11-16.
21. Konkle BA. Clinical challenges within the aging hemophilia population. Thromb Res 2011; 127 (Suppl 1): S10-S13.
22. Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009; 114: 5256-5263.
23. Schutgens RE, Tuinenburg A, Roosendaal G et al. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia 2009; 15: 952-958.
24. Dalldorf FG, Taylor RE, Blatt PM. Arteriosclerosis in severe hemophilia. A postmortem study. Arch Pathol Lab Med 1981; 105: 652-654.
25. Foley CJ, Nichols L, Jeong K et al. Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost 2010; 8: 208-211.
26. Bilora F, Dei RC, Girolami B et al. Do hemophilia A and von Willebrand disease protect against carotid atherosclerosis? A comparative study between coagulopathics and normal subjects by means of carotid echo-color Doppler scan. Clin Appl Thromb Hemost 1999; 5: 232-235.
27. Bilora F, Boccioletti V, Zanon E et al. Hemophilia A, von Willebrand disease, and atherosclerosis of abdominal aorta and leg arteries: factor VIII and von Willebrand factor defects appear to protect abdominal aorta and leg arteries from atherosclerosis. Clin Appl Thromb Hemost 2001; 7: 311-313.
28. Bilora F, Zanon E, Petrobelli F et al. Does hemophilia protect against atherosclerosis? A case-control study. Clin Appl Thromb Hemost 2006; 12: 193-198.
29. Sartori MT, Bilora F, Zanon E et al. Endothelial dysfunction in haemophilia patients. Haemophilia 2008; 14: 1055-1062.
30. Sramek A, Reiber JH, Gerrits WB, Rosendaal FR. Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation 2001; 104: 762-767.
31. Tuinenburg A, Mauser-Bunschoten EP, Verhaar MC et al. Cardiovascular disease in patients with hemophilia. J Thromb Haemost 2009; 7: 247-254.
32. Kulkarni R, Soucie JM, Evatt BL. Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematol 2005; 79: 36-42.
33. Siboni SM, Mannucci PM, Gringeri A et al. Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Haemost 2009; 7: 780-786.
34. Miesbach W, Alesci S, Krekeler S, Seifried E. Comorbidities and bleeding pattern in elderly haemophilia A patients. Haemophilia 2009; 15: 894-899.
35. Ragni MV, Moore CG. Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A. Haemophilia 2011; 17: 867-871.
36. Fransen van de Putte DE, Fischer K et al. Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients. Thromb Res 2012; 130: 157-162.
37. Biere-Rafi S, Baarslag MA, Peters M et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost 2011; 105: 274-278.
38. Fransen van de Putte DE, Fischer K et al. Increased prevalence of hypertension in haemophilia patients. Thromb Haemost 2012; 108: 750-755.
39. Hofstede FG, Fijnvandraat K, Plug I et al. Obesity: a new disaster for haemophilic patients? A nationwide survey. Haemophilia 2008; 14: 1035-1038.
40. Majumdar S, Morris A, Gordon C et al. Alarmingly high prevalence of obesity in haemophilia in the state of Mississippi. Haemophilia 2010; 16: 455-459.
41. Walsh M, Macgregor D, Stuckless S et al. Healthrelated quality of life in a cohort of adult patients with mild hemophilia A. J Thromb Haemost 2008; 6: 755-761.
42. Girolami A, Randi ML, Ruzzon E et al. Myocardial infarction, other arterial thrombosis and invasive coronary procedures, in hemaophilia B: a critical evaluation of reported cases. J Thromb Thrombolysis 2005; 20: 43-46.
43. Girolami A, Ruzzon E, Fabris F et al. Myocardial infarction and other arterial occlusions in hemophilia a patients. A cardiological evaluation of all 42 cases reported in the literature. Acta Haematol 2006; 116: 120-125.
44. Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
45. Fransen van de Putte DE, Schutgens RE, Pulles AE et al. Cardiovascular disease in haemophilia patients. 4-2-0011. EAHAD. Ref Type: Generic.
46. Vidi VD, Matheny ME, Agarwal V et al. Validation of long-term benefits of bivalirudin versus unfractionated heparin in routine clinical practice after percutaneous coronary intervention. Am J Cardiol 2010; 106: 1234-1240.